LOW COST HIV DRUG RESISTANCE MONITORING

低成本 HIV 耐药性监测

• 批准号: 2790154
• 负责人: JACK R. U'REN
• 金额: $ 37.51万
• 依托单位: SAIGENE CORPORATION
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至 2001-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2790154
• 关键词: AIDS /HIV test; DNA primers; HIV infections; diagnosis design /evaluation; drug resistance; human immunodeficiency virus; nucleic acid sequence; polymerase chain reaction; serology /serodiagnosis; technology /technique development; virulence; virus load

DESCRIPTION: (Adapted from Applicant's Abstract) Drug resistance is the single greatest reason for lack of HIV control. Quantitative measurements of viral load and drug resistance can provide the information necessary to rationally modify drug therapy. Increasing viral load can be caused by changes in the immunologic status of the patient or the virulence of the virus or by lack of patient compliance with the difficult drug scheduling. Treating patients who may have been infected with a drug resistant virus with combination drug therapy may be detrimental to the patient. Knowing the precise nature of a drug resistant mutation can also be used to predict cross-resistance or reduced resistance to other drugs. This work will develop RT-PCR conditions, primers, capture sequences, and internal standards that make quantitative detection of wild-type and drug-resistant HIV a simple and rapid process, even while accommodating the known sequence polymorphism found in the virus. In this Phase II study, the developed detection assay for the common reverse transcriptase inhibitors (AZT, ddI, ddC, and 3TC) will be expanded to include the protease inhibitors (indinavir, ritonavir, saquinavir, and nelfinavir) and evaluated using clinical samples. The results from this assay will be compared with the more costly DNA sequencing methods and a competing oligonucleotide ligation assay. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述：（改编自申请人的摘要）耐药性是唯一的 缺乏艾滋病毒控制的最大原因。病毒的定量测量 负荷和耐药性可以提供合理的必要信息 修改药物治疗。病毒载量增加可能是由以下因素引起的： 患者的免疫状态或病毒的毒力或缺乏 患者对困难的药物安排的依从性。治疗以下患者 可能已感染联合药物的耐药病毒 治疗可能对患者有害。了解药物的确切性质 抗性突变也可用于预测交叉抗性或减少 对其他药物产生耐药性。这项工作将开发 RT-PCR 条件、引物、 捕获序列和进行定量检测的内标 野生型和耐药性艾滋病毒是一个简单而快速的过程，即使在 适应病毒中发现的已知序列多态性。在这个阶段 II 研究，开发常见逆转录酶的检测方法 抑制剂（AZT、ddI、ddC 和 3TC）将扩展至包括蛋白酶 抑制剂（茚地那韦、利托那韦、沙奎那韦和奈非那韦）并进行评估 使用临床样本。该测定的结果将与 更昂贵的 DNA 测序方法和竞争性寡核苷酸连接 化验。 拟议的商业应用：不可用